For the normal controls, comparison of the first and second Omnfield indices showed minimal changes. For treated AMD eyes all indices were significantly improved at one month following the first SDM treatment, from 0.06 to 0.1 logMAR among all AREDS groups, but still significantly below the results of the normal controls. The visual field area of acuity equal to or better than 20/40 was improved a significant 26% in the AREDS 1-2 group resulting in near normal values, while the visual field area 20/80 or better was improved, but less and only poorly in the AREDS 3 and 4 groups. Between the first and second treatment episodes (6-8 months) all Omnifield indices improved among the AREDS 1-2 group but declined slightly in the AREDS 3 and 4 groups. Following the second treatment episode all Omnifield indices again improved but with significant variation in the AREDS 1-2 and AREDS 3 groups. The visual field areas >20/40 or >20/80 either remained very stable or worsened slightly but overall remained restricted in relation to normal values.

Among the eyes with reticular pseudodrusen (RPD), a group with known severe risk of progression, significantly worse Omnifield measurements were recorded than among the eyes without the RPD among all AREDS categories. However, the eyes with and without RPD both showed significant improvements in Omnifield indices following SDM, without differences between the groups. These results have demonstrated for the first time the previously unrecognized preservation of functional vision in such eyes at risk of severe vision loss, but indicate that the treatments should be administered early in the course with studies that will follow to evaluate the longer term consequences.